|
|
| 第1行： |
第1行： |
| − | {{Infobox drug
| |
| − | | drug_name = Daraxonrasib
| |
| − | | image = | caption = Daraxonrasib 化学结构
| |
| − | | type = small_molecule
| |
| − | | ALIASES = RMC-6236
| |
| − | | CAS_number = 2765081-21-6
| |
| − | | PubChem = 164726578
| |
| − | | DrugBank =
| |
| − | | UNII = B6T47Y2UAP
| |
| − | | chemical_formula = {{Chembox formula|C=44|H=58|N=8|O=5|S=1}}
| |
| − | | molecular_weight = 811.06 g/mol
| |
| − | | legal_status = Investigational
| |
| − | | legal_status_desc = (研究性药物)
| |
| − | | routes_of_administration = [[口服]]
| |
| − | | class = [[RAS抑制剂]]<br>(RAS(ON) Multi-selective Inhibitor)
| |
| − | | developer = [[Revolution Medicines]]
| |
| − | }}
| |
| | | | |
| − | '''Daraxonrasib'''（研发代号：'''RMC-6236'''）是一种口服的、强效的、多选择性 [[RAS蛋白|RAS]](ON) 抑制剂，由 [[Revolution Medicines]] 公司开发。它是一种具有创新机制的“三复合物”（Tri-complex）抑制剂，主要用于治疗携带 RAS 突变（如 [[KRAS]]、[[NRAS]] 或 [[HRAS]] 的 G12X、G13X、Q61X 突变）的恶性肿瘤，包括[[胰腺导管腺癌]] (PDAC)、[[非小细胞肺癌]] (NSCLC) 和[[结直肠癌]] (CRC)<ref name="Nature2024">{{cite journal | vauthors = Nichols RJ, et al. | title = RMC-6236, a first-in-class, RAS-selective, oral tri-complex RASMULTI(ON) inhibitor | journal = [[Nature (journal)|Nature]] | date = 2024-04 | volume = 629 | issue = 8014 | pages = 917–924 | doi = 10.1038/s41586-024-07379-w | pmid = 38599307 }}</ref>。
| |
| − |
| |
| − | == 参考资料 ==
| |
| − | {{reflist}}
| |